[CAS NO. 2541792-70-3]  ASK1-IN-2

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [2541792-70-3]

Catalog
HY-131969
Brand
MCE
CAS
2541792-70-3

DESCRIPTION [2541792-70-3]

Overview

MDL-
Molecular Weight364.38
Molecular FormulaC19H17FN6O
SMILESO=C(C(N1)=CC2=C1C=C(F)C=C2)NC3=NC(C4=NN=CN4C(C)C)=CC=C3

For research use only. We do not sell to patients.

Summary

ASK1-IN-2 is a potent and orally active inhibitor of apoptosis signal-regulating kinase 1 (ASK1) , with an IC 50 of 32.8 nM. ASK1-IN-2 can be used for the research of ulcerative colitis [1] .


IC50 & Target

ASK1

32.8 nM (IC 50 )


In Vitro

ASK1-IN-2 (compound 19) (10 mM; 1 h) inhibits the luciferase reporter activity in AP1-HEK293 cells, with inhibition rate of 95.59% [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


In Vivo

ASK1-IN-2 (25 mg/kg; p.o. daily for 7 d) improves dextran sulphate sodium (DSS)-induced ulcerative colitis (UC) in mice [1] .
ASK1-IN-2 (25 mg/kg; p.o. daily for 7 d) blocks ASK1-p38/JNK signaling pathways and reduces inflammatory cytokine levels in DSS-induced mouse colon tissues [1] .
ASK1-IN-2 (1 mg/kg; i.v.) shows low clearance (CL=1.38 L/h/kg) and moderate half-life (T 1/2 =1.45 h) in rats [1] .
ASK1-IN-2 (10 mg/kg; p.o.) shows high oral exposure (AUC last =4517 h•ng/mL), 62.2% oral bioavailability and acceptable terminal half-life (T 1/2 =2.31 h) in rats [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male ICR mice (18-22 g, 6-8 weeks) were given 3% DSS (w/v) orally in drinking water [1]
Dosage: 25 mg/kg
Administration: P.o. daily for 7 days
Result: Induced a significant recovery of body weight loss, with an increase of +11.2%.
Decreased the disease activity index (DAI) score about a 2 unit.
Significantly prevented colon shortening.
Attenuated a severe colonic tissue damage and infiltration of inflammatory cells.
Animal Model: Male SD rats [1]
Dosage: 1 mg/kg for i.v.; 10 mg/kg for p.o. (Pharmacokinetic Analysis)
Administration: I.v. and p.o. administration
Result: I.v.: CL=1.38 L/h/kg; T 1/2 =1.45 h.
P.o.: AUC last =4517 h•ng/mL; F=62.2%; T 1/2 =2.31 h.

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro:

DMSO : 250 mg/mL ( 686.10 mM ; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.7444 mL 13.7219 mL 27.4439 mL
5 mM 0.5489 mL 2.7444 mL 5.4888 mL
10 mM 0.2744 mL 1.3722 mL 2.7444 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.08 mg/mL (5.71 mM); Clear solution

  • 2.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 2.08 mg/mL (5.71 mM); Clear solution

* All of the co-solvents are available by MCE.